PARP1 Inhibitor Combined With Oxaliplatin Efficiently Suppresses Oxaliplatin Resistance in Gastric Cancer-Derived Organoids via Homologous Recombination and the Base Excision Repair Pathway

Oxaliplatin (OXA) resistance in the treatment of different types of cancer is an important and complex problem. The culture of tumor organoids derived from gastric cancer can help us to provide a deeper understanding of the underlying mechanisms that lead to OXA resistance. In this study, our purpos...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Huafu, Wang, Chunming, Lan, Linxiang, Wu, Wenhui, Evans, Ian, Ruiz, E. Josue, Yan, Leping, Zhou, Zhijun, Oliveira, Joaquim M., Reis, Rui L., Hu, Zhenran, Chen, Wei, Behrens, Axel, He, Yulong, Zhang, Changhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419238/
https://www.ncbi.nlm.nih.gov/pubmed/34497808
http://dx.doi.org/10.3389/fcell.2021.719192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419238/
https://www.ncbi.nlm.nih.gov/pubmed/34497808
http://dx.doi.org/10.3389/fcell.2021.719192

Ejemplares similares